Co-Diagnostics reports study results for CoSara HPV test
Co-Diagnostics reported study results for CoSara’s HPV test for cervical cancer screening.
Related stories
Polymarket Pauses Trading After $2.65 Million Exploit
Polymarket said it placed its exchange in cancel-only mode and paused relayer actions while investigating a compromise of a third-party provider. More than $2.6 million was lost wi
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC
A. O. Smith Reports Third-Quarter 2026 Revenue of $940.5 Million
Revenue fell 0.2% year over year to $940.5 million. Net income declined 4.3% to $126.3 million, while diluted EPS was $0.93 versus $0.94 a year earlier.
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC
Carrier Reports $2.59 Billion Third-Quarter Loss on $3.1 Billion Impairment
Carrier Global reported third-quarter 2026 revenue of $6.26 billion, up 12.3% year over year, and diluted EPS loss of $3.16. A $3.1 billion goodwill impairment was tied to weaker E
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC
Microsoft Plans Bond Sale to Fund AI Buildout
Microsoft said it is issuing debt in 10 parts, according to a filing.
M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC
US session market picture: S&P 500 -0.62%, Nasdaq 100 -1.7%; EUR/USD +0.06%, WTI -0.64%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.62 percent, Nasdaq futures is down 1.7 percent, Dow futures is down 0.61 percent and Russell futures is up 0.
M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC
Mexedia Signs Equity Investment Agreement for Up to EUR 20 Million
Mexedia signed a fixed-price equity investment agreement with Likan AG for up to EUR 20 million.
M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC